Evaluation of the WARIFA App and Its Impact on Healthy Lifestyle
Launched by INSTITUTO UNIVERSITARIO DE INVESTIGACIONES BIOMÉDICAS Y SANITARIAS (IUIBS) DE LA UNIVERSIDAD DE LAS · Apr 6, 2025
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
The clinical trial is studying the WARIFA app, which aims to help people adopt healthier lifestyles and manage conditions like Type 1 Diabetes (T1D) and other non-communicable diseases (NCDs). Through the app, participants will receive personalized recommendations based on their own health data, with the help of artificial intelligence. The goal is to see how effective the app is in promoting healthy behaviors and managing these conditions over a three-month period.
To participate, you need to be an adult over 18 years old and own a smartphone with internet access. There are two groups in this study: one for people with no more than one NCD (like heart disease, certain cancers, or Type 2 Diabetes) and another for those with Type 1 Diabetes who use insulin. Participants will be randomly assigned to either use the full WARIFA app with AI features or a version without AI. Throughout the study, participants will fill out questionnaires and undergo health checks at the beginning and end to track any changes. If you're interested, this trial is currently recruiting participants until May 2025, so there's still time to get involved!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Common for both population groups:
- • Adults over 18 years of age.
- • Owners of a smartphone operating with Android and with internet access.
- * Group 1: General population:
- • Healthy or diagnosed with no more than one NCD (CVD, any type of cancer, T2D or chronic respiratory disease).
- * Group 2: T1D:
- • Treatment with multiple subcutaneous insulin injections or an insulin pump.
- • Users of a continuous glucose monitor.
- Exclusion Criteria:
- * Common for both groups:
- • Pregnancy.
- • Mobile device which is incompatible with the WARIFA app (E.g. Apple devices).
- • Unable to understand any of the app languages (Spanish, English, Norwegian or Romanian).
- • Any reason which precludes follow-up, based on the researcher's criteria.
- • Group 1: General population
- • People with two or more NCDs.
About Instituto Universitario De Investigaciones Biomédicas Y Sanitarias (Iuibs) De La Universidad De Las
The Instituto Universitario de Investigaciones Biomédicas y Sanitarias (IUIBS) at the Universidad de Las Palmas de Gran Canaria is a leading academic research institution dedicated to advancing biomedical and health sciences. With a focus on translational research, the IUIBS fosters collaboration between researchers, clinicians, and industry partners to develop innovative therapies and improve patient outcomes. The institute is committed to conducting high-quality clinical trials that adhere to ethical standards and regulatory requirements, contributing to the body of knowledge in healthcare and enhancing the overall quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Las Palmas De Gran Canaria, Las Palmas, Spain
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported